Enthera Pharmaceuticals (“Enthera”), a clinical-stage biotech company developing first-in-class antibody therapeutics targeting the Insulin Growth Factor Binding Protein (IGFBP) family for selected inflammatory diseases, confirms its attendance at the European Crohn´s and Colitis Organization – ECCO’24 (ecco-ibd.eu) Conference, scheduled to take place in Stockholm from February 21st to 24th. Enthera will be presenting new preclinical […]

Phase 1 study in healthy volunteers lays groundwork for Ent001 evaluation in patients with inflammatory bowel disease and type 1 diabetes Milan, Italy, March 7, 2023 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions, today announces the start of a Phase 1 first-in-human (FIH) clinical trial with its lead […]

Milano, 4 maggio 2022 – Enthera Pharmaceuticals (“Enthera”), azienda biotecnologica che sviluppa farmaci biologici “first in class” per alcune malattie autoimmuni nelle quali è coinvolto un nuovo meccanismo di apoptosi, annuncia oggi la nomina di Aled Williams a amministratore delegato e membro del suo Consiglio di Amministrazione. Aled ha oltre venticinque anni di esperienza in posizioni […]

New publication titled ‘The IGFBP3/TMEM219 pathway regulates β-cell homeostasis’ published in leading peer-review journal, Nature Communications The research confirms that the recently discovered ‘IGFBP3/TMEM219’ apoptosis pathway plays a key role in beta cell homeostasis, and has the potential to be utilized as a new therapeutic approach for type 1 diabetes Enthera aims to leverage the IGFBP3/TMEM219 pathway to […]

The OpenZone drug discovery unit will be used to support Enthera’s new discovery program and accelerate its mission to identify new treatments for intractable autoimmune diseases Milan, Italy, 7 July 2021 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions based on the discovery of a novel apoptosis pathway, today […]